ICYMI: LGS Foundation Press Release- The U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX®

BOHEMIA, N.Y., June 25, 2018 (LGS Foundation) – The LGS Foundation is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol / CBD) for the…

Continue Reading ICYMI: LGS Foundation Press Release- The U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX®
Will the Case of Billy Caldwell Set a New Precedent for Medical Cannabis in the UK?
Source: Pixabay

Will the Case of Billy Caldwell Set a New Precedent for Medical Cannabis in the UK?

According to a story from uk.news.yahoo.com, when Billy Caldwell, age 12, and his mother returned from traveling to Canada, the Home Office initially confiscated a substance that had been the…

Continue Reading Will the Case of Billy Caldwell Set a New Precedent for Medical Cannabis in the UK?
Avedro Has Begun Patient Enrolment For a Study of a Possible Keratoconus Treatment
Siez18 / Pixabay

Avedro Has Begun Patient Enrolment For a Study of a Possible Keratoconus Treatment

Avedro has announced that patients are now being enrolled in a Phase III trial of an epithelium-on (epi-on) corneal collagen cross-linking procedure designed as a treatment for patients who have…

Continue Reading Avedro Has Begun Patient Enrolment For a Study of a Possible Keratoconus Treatment
First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome
7raysmarketing / Pixabay

First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome

According to a story from the Washington Post, the US Food and Drug Administration (FDA) has cleared the approval of Epidiolex®, a solution whose active ingredient is a refined version…

Continue Reading First Drug Made From Cannabis Approved by the FDA For Dravet Syndrome and Lennox-Gastaut Syndrome
Phase II Trial for Investigational Gaucher Disease Drug Begins
Source: Pixabay

Phase II Trial for Investigational Gaucher Disease Drug Begins

According to a story from GlobeNewsWire, the biopharmaceutical company Orphazyme A/S, which is committed to the development of treatments for patients that are living with rare diseases, has recently announced…

Continue Reading Phase II Trial for Investigational Gaucher Disease Drug Begins
With Its Own Disease Code, Angelman Syndrome Will be Easier to Research and Monitor
Source: Pixabay

With Its Own Disease Code, Angelman Syndrome Will be Easier to Research and Monitor

According to a story from Angelman Syndrome news, Angelman syndrome was recently given its own disease unique disease code: Q93.51. The new code will help make researching and tracking the…

Continue Reading With Its Own Disease Code, Angelman Syndrome Will be Easier to Research and Monitor

Enrollment Has Been Completed For a Clinical Trial of ARO-AAT, an Investigational Therapy for Alpha-1 Antitrypsin Deficiency

Arrowhead Pharmaceuticals, Inc. have announced that they have completed patient enrollment for a Phase 1 clinical trial investigating ARO-AAT, an investigational therapy for the treatment of a genetic liver disease…

Continue Reading Enrollment Has Been Completed For a Clinical Trial of ARO-AAT, an Investigational Therapy for Alpha-1 Antitrypsin Deficiency
Close Menu